Amyotrophic Lateral Sclerosis Treatment Market (2026 - 2033)

Amyotrophic Lateral Sclerosis Treatment Market Summary

The global amyotrophic lateral sclerosis treatment market size was valued at USD 746.7 million in 2025 and is projected to grow from USD 790.0 million in 2026 to USD 1,172.3 million in 2033, at a CAGR of 5.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.5% in 2025. The increasing incidence and prevalence of amyotrophic lateral sclerosis (ALS), particularly sporadic ALS, which affects a large number of patients, is a major driver of market growth.

Furthermore, the growing geriatric population, a key risk factor for ALS, is also contributing to the rise in cases. As the population ages, the demand for effective treatment options is likely to increase.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The growing focus on developing targeted therapies and disease-modifying treatments is expected to drive innovation in the ALS treatment landscape. For instance, in December 2025, Biogen announced that long-term results from the Phase 3 VALOR study and its open-label extension demonstrated that early treatment with QALSODY (tofersen) was associated with a slower decline in clinical function, breathing, and muscle strength in patients with SOD1-associated ALS. The findings highlight the increasing progress in precision medicine and gene-targeted therapies aimed at improving outcomes for ALS patients.

Increased awareness and diagnosis are also key drivers of market growth. Rising awareness among patients and healthcare professionals about ALS and available treatment options is boosting diagnosis rates and driving demand for ALS drugs. This increased awareness is likely to lead to earlier diagnosis and treatment, resulting in better patient outcomes and increased market growth.

Favorable reimbursement policies and expansion of distribution channels are also supporting market growth. In regions such as North America, favorable reimbursement policies for ALS treatments are facilitating access to these therapies and driving market growth. The increasing availability of ALS drugs through hospital pharmacies, retail pharmacies, and online channels is broadening patient access and boosting market growth. As the market continues to evolve, these factors are likely to drive further growth and expansion.

Analyst Perspective

The amyotrophic lateral sclerosis treatment market is experiencing steady growth, driven by increasing awareness of neurodegenerative disorders, rising prevalence of ALS, and growing demand for effective disease management therapies. Medical practitioners and researchers have been shifting their focus towards the development of innovative treatment strategies that can effectively manage the progression of the disease, improve patients' quality of life, and meet the unmet medical needs associated with the condition. The expansion of clinical research, advances in targeted therapies, and investments in drug development in the neurological domain are also fueling market growth. Furthermore, innovative treatment strategies, including gene therapy, biomarker-based therapy, and personalized medicine, are expected to provide new opportunities for market growth. With rising demand for improved treatments and patient-focused care, there are numerous growth opportunities for companies specializing in innovation and development of novel treatment options.

Treatment Insights

The medication segment held the largest market share of over 63.0% in 2025. The market relies heavily on medications as they target the underlying mechanisms of ALS, prolonging survival and improving quality of life. Growing awareness and advancements in drug development drive demand for effective pharmacological options. In addition, increasing efforts in researching and developing new treatment approaches are likely to contribute to the growth of the segment. Furthermore, the availability of approved therapies such as riluzole and edaravone, along with the introduction of novel disease-modifying and gene-targeted treatments, is expanding the therapeutic landscape for ALS patients. Ongoing clinical trials evaluating neuroprotective agents and precision medicine approaches are expected to improve treatment outcomes and support the continued growth of the medication segment over the forecast period.

The stem cell therapy segment is expected to grow at the fastest CAGR over the forecast period. The market is witnessing growing interest in stem cell therapy, which offers potential solutions through cell replacement, neuroprotection, and inflammation modulation. Promising preclinical and clinical trial results indicate that stem cell therapies may slow disease progression and improve patient outcomes, driving demand and research. In addition, advances in regenerative medicine and cell engineering technologies are enhancing the safety, efficacy, and scalability of stem cell-based treatments. Increasing investments from biotechnology companies, research institutions, and government organizations are further accelerating the development of stem cell therapies for ALS. As clinical evidence continues to emerge, stem cell-based approaches are expected to become an important component of future ALS treatment strategies.

Type Insights

The sporadic ALS segment held the largest market share, at approximately 87.5%, in 2025. The growth of the segment is driven by its increasing incidence among the aging population and rising awareness of the disease. As sporadic ALS lacks a clear genetic link, it presents unique challenges and opportunities for research and drug development, driving demand and growth for FDA-approved medications such as Riluzole and Edaravone. The absence of an identifiable genetic cause in sporadic ALS has prompted researchers to explore a broad range of potential disease mechanisms, including oxidative stress, glutamate excitotoxicity, neuroinflammation, and TDP-43 protein aggregation, each of which represents a distinct therapeutic target for next-generation drug development. In addition, the growing adoption of biomarkers such as neurofilament light chain (NfL) in clinical trial design is accelerating the identification of effective therapies for sporadic ALS by enabling earlier detection of disease activity and more precise measurement of treatment response.

The familial ALS segment is expected to grow at the fastest CAGR over the forecast period. The market is witnessing growth owing to its hereditary nature, with a 50% chance of transmission to offspring. Increased awareness and genetic testing have led to better identification of familial cases, contributing to a rise in reported instances. Research into genetic factors drives interest in targeted therapies, elevating FALS’ profile in the treatment landscape. The identification of key genetic mutations including SOD1, C9orf72, FUS, and TARDBP, has paved the way for the development of precision medicine approaches such as antisense oligonucleotides and gene-silencing therapies that directly target the underlying molecular cause of familial ALS. The success of tofersen (Qalsody) as the first FDA-approved genetically targeted ALS therapy has validated the antisense oligonucleotide platform, generating strong momentum for the development of similar precision therapies targeting other familial ALS mutations, particularly C9orf72, which accounts for up to 40% of familial cases.

Distribution Channel Insights

The hospital pharmacies segment held the largest market share of approximately 58.5% in 2025. ALS patients require frequent hospital stays and visits for treatment, leading to increased demand for hospital pharmacies. Patients also prefer hospital pharmacies due to easy access to a wide range of ALS drugs and adequate stock, further driving segment growth. Hospital pharmacies play a particularly critical role in the dispensing of specialty ALS therapies such as Qalsody (tofersen), which requires intrathecal administration via lumbar puncture by trained healthcare professionals in a clinical setting, making hospital-based dispensing an essential component of the treatment pathway. The complex medication management needs of ALS patients including multidrug regimens, intravenous infusions, and close monitoring for adverse events, further reinforce the centrality of hospital pharmacies in ensuring safe and coordinated drug delivery.

The retail pharmacies segment is expected to grow at the fastest CAGR over the forecast period. The market is witnessing growth aided by its accessibility and convenience for patients. Retail pharmacies provide easy access to essential medications and offer personalized services, including medication counseling and management support. This combination of convenience and personalized care drives the popularity of retail pharmacies in the ALS treatment landscape, enhancing patient reach and patient satisfaction. The growing availability of oral ALS medications, particularly Riluzole, which is widely stocked at regular retail pharmacies and covered by most insurance plans has significantly expanded the role of retail pharmacies in serving ALS patients who prefer to manage their treatment from home. The transition of edaravone from intravenous infusion to an oral formulation (RADICAVA ORS) has further broadened the scope of retail pharmacy dispensing in the ALS treatment landscape, enabling patients to receive their medication through specialty retail and community pharmacies rather than hospital infusion centers.

Regional Insights

North America amyotrophic lateral sclerosis treatment industry dominated the global market, accounting for over 37.5% of revenue in 2025. Amyotrophic Lateral Sclerosis Treatment is driven by high disease prevalence, significant healthcare expenditure, and advanced healthcare infrastructure. The presence of major pharmaceutical companies and favorable reimbursement policies facilitate innovation and patient access to essential drugs. Ongoing research initiatives and increased awareness about ALS further drive market growth, positioning North America as a leader in ALS treatment advancements and improving patient outcomes.

To learn more about this report, Download Free Sample Report

U.S. Amyotrophic Lateral Sclerosis Treatment Market Trends

The amyotrophic lateral sclerosis treatment industry in the U.S. dominated the North America region in 2025, driven by high disease prevalence, significant healthcare expenditure, and advanced healthcare infrastructure. Increased awareness and collaborative efforts between pharmaceutical companies and research institutions position the country as a leader in ALS therapeutic advancements.

Europe Amyotrophic Lateral Sclerosis Treatment Market Trends

Europe amyotrophic lateral sclerosis treatment industry held substantial market share in 2025. The region benefits from robust research initiatives, advanced healthcare infrastructure, and collaborative efforts among pharmaceutical companies, academic institutions, and healthcare providers. Increasing awareness and supportive regulatory frameworks promote the adoption of new treatments, driving market growth and positioning Europe as a hub for ALS research and advancements.

The amyotrophic lateral sclerosis treatment industry in Germany is expected to grow over the forecast period, fueled by strong research initiatives, advanced healthcare infrastructure, and collaborative efforts among pharmaceutical companies, academic institutions, and healthcare providers. Increasing awareness and supportive regulatory frameworks promote adoption of new treatments, while personalized medicine and targeted interventions fuel market expansion.

Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market

The Asia Pacific amyotrophic lateral sclerosis treatment industry is expected to grow at the fastest CAGR over the forecast period. The growth in the market is aided by rising healthcare investments, increasing awareness, and improved healthcare infrastructure in countries such as Japan, China, and South Korea. The growing incidence of neurodegenerative diseases and innovative therapies fuel market growth. In addition, increasing adoption of advanced diagnostic approaches and expanding access to specialized neurological care are supporting the demand for ALS treatment solutions. Furthermore, ongoing clinical research and development activities for targeted therapies are expected to create new growth opportunities in the region.

The amyotrophic lateral sclerosis treatment industry in China is anticipated to register significant growth over the forecast period. Market growth in the country is propelled by increasing healthcare investments, government initiatives, and emerging innovative therapies. Improving healthcare infrastructure, growing incidence of ALS, and pharmaceutical company attention to clinical trials enhance diagnosis and treatment options, contributing to significant market growth potential.

Key Amyotrophic Lateral Sclerosis Treatment Company Insights

Some key companies operating in the market include Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corporation); Biogen; BrainStorm Cell Limited; Amylyx Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc.; among others. Strategic partnerships between pharmaceutical companies and research institutions are accelerating drug development and clinical trials, driving demand for effective treatments and creating opportunities for emerging players.

• Biogen Inc. is dedicated to developing innovative therapies for neurological diseases, including ALS. Their notable product, QALSODY, is the first therapy targeting the genetic cause of SOD1-ALS, approved by the FDA and recommended for EMA marketing authorization.
• Sanofi focuses on innovation and collaboration, driving advancements in ALS treatment options worldwide. Sanofi’s commitment to addressing unmet medical needs through research and partnerships positions it as a significant player in the market.

Key Amyotrophic Lateral Sclerosis Treatment Companies

The following key companies have been profiled for this study on amyotrophic lateral sclerosis treatment market:

• Tanabe Pharma Corporation

• Biogen

• BrainStorm Cell Limited

• Amylyx Pharmaceuticals, Inc.

• Ionis Pharmaceuticals, Inc.

• Sanofi

• Otsuka Pharmaceutical Co., Ltd.

• F. Hoffmann-La Roche Ltd

• AB Science

• Sun Pharmaceutical Industries Ltd.

• Orion Corporation

• CORESTEMCHEMON Inc.

Recent Developments

• In November 2024, BrainStorm Cell Therapeutics entered into a strategic partnership with Pluri to support manufacturing activities for the Phase 3b clinical trial of NurOwn, its investigational stem cell therapy for ALS. The partnership is intended to strengthen production capabilities and support the advancement of regenerative medicine approaches for ALS treatment.

• In June 2024, Mitsubishi Tanabe Pharma Corporation transferred its European argatroban business to Ethypharm, focusing on Radicava’s treatment agent for ALS in the region.

Amyotrophic Lateral Sclerosis Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global amyotrophic lateral sclerosis treatment market report by treatment, type, distribution channel, and region:

• Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Medication
    • Riluzole
    • Edaravone
    • Others
  • Stem Cell Therapy
  • Others
• Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Sporadic ALS
  • Familial ALS
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait